Fiducial Markers for Stereotactic Lung Radiation Therapy: Review of the Transthoracic, Endovascular and Endobronchial Approaches

Overview

Journal Eur Respir Rev

Specialty Pulmonary Medicine

Date 2022 Jan 13

PMID 35022258

Authors

Alessio Casutt

Remy Kinj

Esat-Mahmut Ozsahin

Christophe von Garnier

Alban Lovis

Affiliations

Soon will be listed here.

Abstract

Stereotactic body radiation therapy is an alternative to surgery for early-stage, inoperable peripheral non-small cell lung cancer. As opposed to linear accelerator (linac)-based ( gating) and free-breathing techniques, CyberKnife® with Synchrony® technology allows accurate radiation delivery by means of a real-time respiratory motion tracking system using, in most cases, metal fiducial markers (FMs) placed in the vicinity of the target. The aims of this review are as follows. First, to describe the safety and efficacy of the transthoracic, endovascular and endobronchial FM insertion techniques for peripheral pulmonary lesions (PPLs). Second, to analyse performance in terms of the migration and tracking rates of different FM types. Recent developments in FM tracking for central lesions will also be reviewed. In conclusion, for PPLs, the endobronchial approach provides a low rate of pneumothorax, offers the possibility of concurrent diagnostic sampling for both the PPL and the lymph nodes, and, finally, reduces the intervention time compared to other techniques. In this context, coil-tailed and coil-spring FMs have shown the lowest migration rate with a consequently high tracking rate.

Citing Articles

Stereotactic Lung Re-Irradiation After a First Course of Stereotactic Radiotherapy with In-Field Relapse: A Valuable Option to Be Considered.

Sahin A, Romano E, Casutt A, Moeckli R, Vallet V, El Chammah S Cancers (Basel). 2025; 17(3).

PMID: 39941736 PMC: 11815762. DOI: 10.3390/cancers17030366.

Recent progress in radioactive seed implantation brachytherapy of non-small cell lung cancer: a narrative review.

Wang X, Tian S, Shi H, Qin H, Zhang W, Dong Y J Thorac Dis. 2024; 16(3):2167-2176.

PMID: 38617768 PMC: 11009575. DOI: 10.21037/jtd-23-1600.

Intra- and inter-fractional variations of tumors with fiducial markers measured using respiratory-correlated computed tomography images for respiratory gated lung stereotactic body radiation therapy.

Manabe Y, Shiinoki T, Fujimoto K, Ueda K, Karita M, Ono T J Appl Clin Med Phys. 2024; 25(6):e14280.

PMID: 38252745 PMC: 11163493. DOI: 10.1002/acm2.14280.

Cycle-generative adversarial network-based bone suppression imaging for highly accurate markerless motion tracking of lung tumors for cyberknife irradiation therapy.

Mochizuki Z, Saito M, Suzuki T, Mochizuki K, Hasegawa J, Nemoto H J Appl Clin Med Phys. 2023; 25(1):e14212.

PMID: 37985163 PMC: 10795441. DOI: 10.1002/acm2.14212.

The evolution of endobronchial ultrasound usage in modern era.

Gurun Kaya A, Dogan D Tuberk Toraks. 2023; 71(3):299-307.

PMID: 37740633 PMC: 10795244. DOI: 10.5578/tt.20239711.

References

Seides B, Egan 3rd J, French K, Kovitz K, Desai N . Fiducial marker placement for stereotactic body radiation therapy via convex probe endobronchial ultrasound: a case series and review of literature. J Thorac Dis. 2018; 10(3):1972-1983. PMC: 5906232. DOI: 10.21037/jtd.2018.03.49. View

Lachkar S, Guisier F, Roger M, Obstoy B, Bota S, Lerouge D . Assessment of Per-Endoscopic Placement of Fiducial Gold Markers for Small Peripheral Lung Nodules < 20 mm Before Stereotactic Radiation Therapy. Chest. 2017; 153(2):387-394. DOI: 10.1016/j.chest.2017.08.016. View

Mongeon M, Thibault F, Chartrand-Lefebvre C, Gorgos A, Soulez G, Filion E . Safety and Efficacy of Endovascular Fiducial Marker Insertion for CyberKnife Stereotactic Radiation Therapy Planning in Early-Stage Lung Cancer. J Vasc Interv Radiol. 2017; 28(8):1090-1097. DOI: 10.1016/j.jvir.2017.05.010. View

Bowling M, Folch E, Khandhar S, Kazakov J, Krimsky W, LeMense G . Fiducial marker placement with electromagnetic navigation bronchoscopy: a subgroup analysis of the prospective, multicenter NAVIGATE study. Ther Adv Respir Dis. 2019; 13:1753466619841234. PMC: 6454637. DOI: 10.1177/1753466619841234. View

Chang J, Bezjak A, Mornex F . Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned. J Thorac Oncol. 2014; 10(4):577-85. DOI: 10.1097/JTO.0000000000000453. View

Rowe B, Boffa D, Wilson L, Kim A, Detterbeck F, Decker R . Stereotactic body radiotherapy for central lung tumors. J Thorac Oncol. 2012; 7(9):1394-9. DOI: 10.1097/JTO.0b013e3182614bf3. View

Ceder Y, Fenig E, Popvtzer A, Peled N, Kramer M, Saute M . Stereotactic body radiotherapy for central lung tumors, yes we can!. Radiat Oncol. 2018; 13(1):77. PMC: 5918762. DOI: 10.1186/s13014-018-1017-y. View

Yousefi S, Collins B, Reichner C, Anderson E, Jamis-Dow C, Gagnon G . Complications of thoracic computed tomography-guided fiducial placement for the purpose of stereotactic body radiation therapy. Clin Lung Cancer. 2007; 8(4):252-6. DOI: 10.3816/CLC.2007.n.002. View

Hagmeyer L, Priegnitz C, Kocher M, Schilcher B, Budach W, Treml M . Fiducial marker placement via conventional or electromagnetic navigation bronchoscopy (ENB): an interdisciplinary approach to the curative management of lung cancer. Clin Respir J. 2014; 10(3):291-7. DOI: 10.1111/crj.12214. View

10.

Shepherd R, Weiss E . Convex Endobronchial Ultrasound-Guided Placement of Fiducial Markers in Central Lung Tumors. J Bronchology Interv Pulmonol. 2017; 24(2):e25-e26. PMC: 5411857. DOI: 10.1097/LBR.0000000000000361. View

11.

Purdie T, Bissonnette J, Franks K, Bezjak A, Payne D, Sie F . Cone-beam computed tomography for on-line image guidance of lung stereotactic radiotherapy: localization, verification, and intrafraction tumor position. Int J Radiat Oncol Biol Phys. 2007; 68(1):243-52. DOI: 10.1016/j.ijrobp.2006.12.022. View

12.

Wong J, Sharpe M, Jaffray D, Kini V, Robertson J, Stromberg J . The use of active breathing control (ABC) to reduce margin for breathing motion. Int J Radiat Oncol Biol Phys. 1999; 44(4):911-9. DOI: 10.1016/s0360-3016(99)00056-5. View

13.

Harley D, Krimsky W, Sarkar S, Highfield D, Aygun C, Gurses B . Fiducial marker placement using endobronchial ultrasound and navigational bronchoscopy for stereotactic radiosurgery: an alternative strategy. Ann Thorac Surg. 2010; 89(2):368-73. DOI: 10.1016/j.athoracsur.2009.09.048. View

14.

Ding C, Chang C, Haslam J, Timmerman R, Solberg T . A dosimetric comparison of stereotactic body radiation therapy techniques for lung cancer: robotic versus conventional linac-based systems. J Appl Clin Med Phys. 2010; 11(3):3223. PMC: 5720432. DOI: 10.1120/jacmp.v11i3.3223. View

15.

Kilby W, Dooley J, Kuduvalli G, Sayeh S, Maurer Jr C . The CyberKnife Robotic Radiosurgery System in 2010. Technol Cancer Res Treat. 2010; 9(5):433-52. DOI: 10.1177/153303461000900502. View

16.

Schroeder C, Hejal R, Linden P . Coil spring fiducial markers placed safely using navigation bronchoscopy in inoperable patients allows accurate delivery of CyberKnife stereotactic radiosurgery. J Thorac Cardiovasc Surg. 2010; 140(5):1137-42. DOI: 10.1016/j.jtcvs.2010.07.085. View

17.

Renier H, Gerard L, Lamborelle P, Cousin F . Efficacy of the tract embolization technique with gelatin sponge slurry to reduce pneumothorax and chest tube placement after percutaneous CT-guided lung biopsy. Cardiovasc Intervent Radiol. 2019; 43(4):597-603. DOI: 10.1007/s00270-019-02387-3. View

18.

Lachkar S, Guisier F, Roger M, Bota S, Lerouge D, Piton N . A simple endoscopic method with radial endobronchial ultrasonography for low-migration rate coil-tailed fiducial marker placement. J Thorac Dis. 2020; 12(4):1467-1474. PMC: 7212149. DOI: 10.21037/jtd.2020.02.37. View

19.

Bang A, Bezjak A . Stereotactic body radiotherapy for centrally located stage I non-small cell lung cancer. Transl Lung Cancer Res. 2019; 8(1):58-69. PMC: 6351397. DOI: 10.21037/tlcr.2018.10.07. View

20.

Arnett A, Mou B, Owen D, Park S, Nelson K, Hallemeier C . Long-term Clinical Outcomes and Safety Profile of SBRT for Centrally Located NSCLC. Adv Radiat Oncol. 2019; 4(2):422-428. PMC: 6460233. DOI: 10.1016/j.adro.2019.01.002. View